retatrutide eli lilly The result of the late stage trial is another boost to Lilly's booming obesity business — weight-loss drugs have helped propel the US company to become the first pharmaceuticals group to An experimental weight-loss drug from

The SELECT study with semaglutide will report results only in 2023 and tirzepatide is being tested in patients with diabetes in the SURPASS-CVOT

It stimulates melanin production, allowing users to achieve a more profound and longer-lasting tan without prolonged sun exposure

Selectivity profiling against ACTH/cortisol/prolactin readouts

10.16965/ijar.2019.160 23

CVS said its pharmacy benefits manager, Caremark, seeks to expand access to weight-loss drugs by using competition to drive lower costs. Bloomberg News reported in May 2025 that Caremark secured a steep discount from pharmaceutical company Novo Nordisk to make Wegovy a preferred option over competing GLP-1 medications, a move projected to save some health plans up to 15% on annual anti-obesity drug costs